Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
NCT04504526
Summary
Chemokine receptor CXCR4 is normally expressed on T-lymphocytes, B-lymphocytes, monocytes, macrophages, neutrophils and eosinophils as well as hematopoietic stem and progenitor cells (HSPC) in the bone marrow. 68Ga-Pentixafor PET/CT represents a promising method for the in vivo assessment of the CXCR4 expression status in cancer patients, especially in hematologic malignancies. This prospective study is going to investigate whether metabolic characterization by 68Ga-Pentixafor PET/CT may be superior for diagnosis, risk stratification, and the prognostic evaluation in lymphoproliferative diseases.
Eligibility
Inclusion Criteria: * suspected or confirmed untreated Lymphoproliferative diseases patients * 18F-FDG PET/CT within two weeks * signed written consent. Exclusion Criteria: * pregnancy * breastfeeding * known allergy against Pentixafor
Conditions4
Interventions1
Related trials
- CXCR4-targeted PET/CT Imaging in Hematological Malignancies — Zhongnan Hospital
- In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET — Memorial Sloan Kettering Cancer Center
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT04504526